264 related articles for article (PubMed ID: 25732051)
1. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
[TBL] [Abstract][Full Text] [Related]
2. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.
He X; Liao J; Liu F; Yan J; Yan J; Shang H; Dou Q; Chang Y; Lin J; Song Y
Oncotarget; 2015 Feb; 6(4):2034-45. PubMed ID: 25576916
[TBL] [Abstract][Full Text] [Related]
3. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
4. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
5. CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.
He XX; Zhang YN; Yan JW; Yan JJ; Wu Q; Song YH
Tumour Biol; 2016 Jan; 37(1):807-15. PubMed ID: 26250460
[TBL] [Abstract][Full Text] [Related]
6. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.
Shin KS; Sullenger BA; Lee SW
Mol Ther; 2004 Aug; 10(2):365-72. PubMed ID: 15294183
[TBL] [Abstract][Full Text] [Related]
7. CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.
He X; Kong X; Yan J; Yan J; Zhang Y; Wu Q; Chang Y; Shang H; Dou Q; Song Y; Liu F
Tumour Biol; 2015 Mar; 36(3):1437-44. PubMed ID: 25663456
[TBL] [Abstract][Full Text] [Related]
8. [ShRNA-mediated silencing of MDM2 inhibits growth of HepG2 hepatocellular carcinoma cells xenografted in nude mice].
Zhao YY; Li YG; Sun YJ; Liu HP; Yang ZC; Zhang DD; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):213-7. PubMed ID: 23967744
[TBL] [Abstract][Full Text] [Related]
9. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53.
Stähler F; Roemer K
Oncogene; 1998 Dec; 17(26):3507-12. PubMed ID: 10030675
[TBL] [Abstract][Full Text] [Related]
11. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
12. Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma.
Liu L; Liu Y; Chen X; Wang M; Zhou Y; Zhou P; Li W; Zhu F
Oncotarget; 2017 Jul; 8(27):43990-44003. PubMed ID: 28410205
[TBL] [Abstract][Full Text] [Related]
13. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling.
Lu WJ; Chua MS; So SK
Oncotarget; 2015 Dec; 6(39):41722-35. PubMed ID: 26497681
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
15. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
16. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
[TBL] [Abstract][Full Text] [Related]
17. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro.
Lai PB; Chi TY; Chen GG
Apoptosis; 2007 Feb; 12(2):387-93. PubMed ID: 17191126
[TBL] [Abstract][Full Text] [Related]
18. PIN1 in hepatocellular carcinoma is associated with TP53 gene status.
Bae JS; Noh SJ; Kim KM; Jang KY; Park HS; Chung MJ; Park BH; Moon WS
Oncol Rep; 2016 Oct; 36(4):2405-11. PubMed ID: 27499097
[TBL] [Abstract][Full Text] [Related]
19. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
